Mesoblast (NASDAQ:MESO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday. The brokerage currently has a $6.25 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 6.11% from the company’s current price.
According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “
Several other analysts have also recently issued reports on the company. Maxim Group reissued a “buy” rating and issued a $14.00 target price on shares of Mesoblast in a research note on Tuesday, September 26th. Oppenheimer set a $16.00 target price on Mesoblast and gave the stock a “buy” rating in a research note on Wednesday, December 20th. Finally, ValuEngine cut Mesoblast from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $13.11.
COPYRIGHT VIOLATION WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2018/01/13/mesoblast-meso-rating-increased-to-buy-at-zacks-investment-research.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.